Elizabeth Urbanek Clinical Supply Leader Articles
-
Merck Ends Nemtabrutinib Development, Closing Three Phase 3 BELLWAVE Trials
11/20/2026
Merck has discontinued nemtabrutinib development and three Phase 3 trials, leaving clinical supply teams to coordinate IMP returns, comparator inventory, reconciliation and program-wide close-out.
-
Los Angeles And Long Beach Port Talks Stall Ahead Of Saturday Strike Deadline
11/19/2026
Contract talks at the Los Angeles and Long Beach ports have stalled ahead of a Nov. 21 strike deadline, putting inbound clinical trial shipments, refrigerated containers and U.S. depot inventory at risk.
-
FDA Launches Program To Share Approval Reviews With Foreign Regulators, Expanding To Novel Drugs In 2027
11/18/2026
FDA's Global Reliance Disclosure Program could shorten foreign drug approvals, affecting continued-access supply, country-specific labeling, and IMP distribution timelines.
-
FDA Rejects Summit's Ivonescimab, Citing Lack Of Statistically Significant Overall Survival Benefit
11/17/2026
FDA's rejection of ivonescimab raises questions about longer survival-driven trials, investigational drug inventory, comparator sourcing, and clinical supply forecasting.
-
Shenzhen APEC Restrictions And Bangkok Cargo Backlog Squeeze Air Freight Lanes Into South China And Thailand
11/13/2026
Shenzhen APEC cargo restrictions and a Bangkok warehouse backlog threaten air freight capacity and temperature-sensitive pharmaceutical shipments moving into Asia.
-
Identity Security In Clinical Trial Supply: Who Has Access, And Why?
11/13/2026
Explore how identity verification, role-based access, and audit trails help protect clinical trial supply systems from unauthorized changes, identity fraud, and access risks.
-
FDA Draft Guidance Spells Out Dose Escalation And Expansion Expectations For Early-Phase Solid Tumor Trials
11/12/2026
FDA draft guidance outlines dose escalation and expansion expectations for early-phase solid tumor trials, with implications for IMP presentations and clinical supply planning.
-
Kalaris Expects TH103 Data In Second Half Of 2027 After Clinical Batch Misses Specification
11/11/2026
Kalaris Therapeutics delays TH103 trial data after a manufacturing batch fails release testing, highlighting the supply risks of single-batch clinical programs.
-
Los Angeles And Long Beach Port Strike Deadline Moves To Nov. 20, Keeping Ocean Freight Risk In Play
11/10/2026
Contract talks at Los Angeles and Long Beach ports extend to Nov. 20, leaving ocean shipments of clinical trial materials exposed to potential delays and disruption.
-
FDA Investigates Zolgensma Malignancy Risk, Puts Other AAV Gene Therapy Programs On Watch
11/9/2026
FDA investigation of Zolgensma-related malignancy risk puts AAV gene therapy sponsors on alert for potential dosing delays, inventory impacts and clinical trial supply decisions.